The decision to expand or not expand Medicaid has had implications across the healthcare industry, and there are some results that are not entirely unexpected, explained Austin Frakt, PhD. For instance, studies have found that in non-expansion states, health insurance coverage rates are lower and grow slower than in expansion states. Additionally, the choice not to expand the federal program means a state is missing out on federal dollars, he said.
“So states that haven’t expanded, they’re not benefiting from that,” Dr Frakt said. “So you’re seeing hospitals with tighter margins, maybe negative margins, some closures in rural areas, and the state in general is not getting an economic boost that it would otherwise.”
The question is not so much “should we expand coverage?” as much as it is “what is the best way to go about bringing new insurance coverage to low-income Americans,” said Matt Salo. So even before the implementation of the Affordable Care Act and state decisions on Medicaid expansion, there were changes happening to state Medicaid programs, such as delivery system and payment reform.
One opportunity is maternity care, Margaret E. O’Kane, MHA, pointed out. More than half of births are in Medicaid, and there are opportunities to improve birth outcomes. Leah Binder echoed the sentiment. Her organization, The Leapfrog Group, has seen early elective deliveries drop through the efforts of some states that have made an effort to align the interests of Medicaid and private sector purchasers.
“It really is about creating the right synergy with the delivery system,” O’Kane said. “And the conditions on the ground in each state are different, and taking advantage of the natural resources that you might have in the state or the natural advantages, I think, is part of the magic.”
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More